title: Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.
authors.forename: Massimo
authors.initials: M
authors.lastname: Colombo
mesh_terms: D004359:Drug Therapy, Combination; D058625:End Stage Liver Disease / Q000517:prevention & control*; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons